Skip to main content

Corvus Pharmaceuticals, Inc.

CRVS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001626971

No open-market purchases or sales by Corvus Pharmaceuticals, Inc. insiders were filed in the last 90 days; 173 institutions reported holding it in 13F filings for Q2 2026, worth $1.06B in total; no superinvestor holds it.

13F holders, Q2 2026

Institutional positions in Corvus Pharmaceuticals, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
173
+10 vs. Q1 2026
Shares held
70.7M
+728.8K (+1.0%) vs. Q1 2026
Total value
$1.06B
+$33.1M (+3.2%) vs. Q1 2026
New holders
40
70 more added
Sold out
30
40 more reduced

1 institution that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q1 2026: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting CRVS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ2 2026: 173 institutions
Q1 2021: 49 institutionsQ2 2021: 50 institutionsQ3 2021: 61 institutionsQ4 2021: 62 institutionsQ1 2022: 57 institutionsQ2 2022: 47 institutionsQ3 2022: 48 institutionsQ4 2022: 42 institutionsQ1 2023: 37 institutionsQ2 2023: 52 institutionsQ3 2023: 52 institutionsQ4 2023: 48 institutionsQ1 2024: 47 institutionsQ2 2024: 47 institutionsQ3 2024: 62 institutionsQ4 2024: 86 institutionsQ1 2025: 88 institutionsQ2 2025: 92 institutionsQ3 2025: 103 institutionsQ4 2025: 124 institutionsQ1 2026: 164 institutionsQ2 2026: 173 institutions
Value heldQ2 2026: $1.06B
Q1 2021: $62.8MQ2 2021: $63.2MQ3 2021: $136.4MQ4 2021: $66.7MQ1 2022: $44.9MQ2 2022: $25.4MQ3 2022: $18.1MQ4 2022: $18.2MQ1 2023: $18.9MQ2 2023: $44.6MQ3 2023: $28.0MQ4 2023: $33.8MQ1 2024: $31.9MQ2 2024: $50.2MQ3 2024: $158.5MQ4 2024: $202.0MQ1 2025: $115.4MQ2 2025: $167.1MQ3 2025: $312.7MQ4 2025: $359.4MQ1 2026: $1.02BQ2 2026: $1.06B
Institutions holding CRVS and their total value by quarter
QuarterHoldersValue
Q2 2026173$1.06B
Q1 2026164$1.02B
Q4 2025124$359.4M
Q3 2025103$312.7M
Q2 202592$167.1M
Q1 202588$115.4M
Q4 202486$202.0M
Q3 202462$158.5M
Q2 202447$50.2M
Q1 202447$31.9M
Q4 202348$33.8M
Q3 202352$28.0M
Q2 202352$44.6M
Q1 202337$18.9M
Q4 202242$18.2M
Q3 202248$18.1M
Q2 202247$25.4M
Q1 202257$44.9M
Q4 202162$66.7M
Q3 202161$136.4M
Q2 202150$63.2M
Q1 202149$62.8M

Institutions, Q2 2026

Shares, value and share of portfolio for each institution holding Corvus Pharmaceuticals, Inc.; share changes are against Q1 2026.

Institutions holding CRVS in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
MAI Capital Management0$00.00%−7−100.0%Sold out
Twin Peaks Wealth Advisors, LLC0$00.00%−7−100.0%Sold out
Advisory Services Network, LLC0$00.00%−1−100.0%Sold out
CWM, LLC––––Not filed